Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ANAB

ANAB - AnaptysBio Inc Stock Price, Fair Value and News

25.49USD+1.66 (+6.97%)Market Closed
Watchlist

Market Summary

USD25.49+1.66
Market Closed
6.97%

ANAB Alerts

  • Point72 Asset Management, L.P. reported owning 3% of ANAB [2024-02-14]

ANAB Stock Price

View Fullscreen

ANAB RSI Chart

ANAB Valuation

Market Cap

677.4M

Price/Earnings (Trailing)

-4.58

Price/Sales (Trailing)

32.93

EV/EBITDA

-4.36

Price/Free Cashflow

-6.92

ANAB Price/Sales (Trailing)

ANAB Profitability

EBT Margin

-625.70%

Return on Equity

-122.79%

Return on Assets

-30.33%

Free Cashflow Yield

-14.44%

ANAB Fundamentals

ANAB Revenue

Revenue (TTM)

20.6M

Rev. Growth (Yr)

114.59%

Rev. Growth (Qtr)

4.32%

ANAB Earnings

Earnings (TTM)

-147.8M

Earnings Growth (Yr)

-11.36%

Earnings Growth (Qtr)

6.37%

Breaking Down ANAB Revenue

Last 7 days

4.7%

Last 30 days

4.1%

Last 90 days

61.7%

Trailing 12 Months

-6.6%

How does ANAB drawdown profile look like?

ANAB Financial Health

Current Ratio

10.92

ANAB Investor Care

Buy Backs (1Y)

6.53%

Diluted EPS (TTM)

-5.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202314.4M18.0M20.6M0
202250.0M36.7M23.5M10.3M
202171.2M101.3M122.2M63.2M
202023.0M18.0M18.0M75.0M
20195.8M6.5M7.3M8.0M
20182.5M3.3M4.2M5.0M
201712.9M9.2M5.4M1.6M
201617.3M17.1M16.9M16.7M
201500017.6M

Tracking the Latest Insider Buys and Sells of AnaptysBio Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 30, 2024
mulroy dennis
sold
-72,425
23.6298
-3,065
chief financial officer
Jan 08, 2024
loumeau eric j
sold
-50,272
21.81
-2,305
chief legal officer
Jan 08, 2024
lizzul paul f.
sold
-55,702
21.81
-2,554
chief medical officer
Jan 08, 2024
mulroy dennis
sold
-47,545
21.81
-2,180
chief financial officer
Jan 08, 2024
faga daniel
sold
-149,747
21.81
-6,866
ceo
Jan 06, 2024
lizzul paul f.
acquired
-
-
6,145
chief medical officer
Jan 06, 2024
loumeau eric j
acquired
-
-
5,545
chief legal officer
Jan 06, 2024
mulroy dennis
acquired
-
-
5,245
chief financial officer
Jan 06, 2024
faga daniel
acquired
-
-
17,850
ceo
Nov 22, 2023
loumeau eric j
sold
-12,515
14.19
-882
chief legal officer

1–10 of 50

Which funds bought or sold ANAB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
unchanged
-
1,477,420
9,146,340
0.15%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
sold off
-100
-416,000
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
2.42
900,000
4,965,000
-%
Feb 15, 2024
Palo Alto Investors LP
added
59.29
6,968,230
14,713,000
1.33%
Feb 15, 2024
BARCLAYS PLC
reduced
-18.74
-19,000
628,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
added
6.25
77.00
364
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
17.29
183,877
644,892
-%
Feb 15, 2024
Virtus ETF Advisers LLC
reduced
-8.66
8,543
104,144
0.07%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
56,414
349,232
-%
Feb 14, 2024
VANGUARD GROUP INC
reduced
-18.95
-1,019,880
29,562,100
-%

1–10 of 47

Are Funds Buying or Selling ANAB?

Are funds buying ANAB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANAB
No. of Funds

Unveiling AnaptysBio Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
7.67%
2,036,990
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
3.0%
788,545
SC 13G/A
Feb 14, 2024
tang capital partners lp
7.3%
1,950,609
SC 13G/A
Feb 13, 2024
vanguard group inc
5.19%
1,380,115
SC 13G/A
Jan 26, 2024
blackrock inc.
6.8%
1,799,823
SC 13G/A
Oct 02, 2023
deep track capital, lp
5.12%
1,360,176
SC 13G
Feb 14, 2023
point72 asset management, l.p.
7.5%
2,124,200
SC 13G/A
Feb 10, 2023
flynn james e
4.09%
1,161,826
SC 13G/A
Feb 09, 2023
federated hermes, inc.
4.93%
1,401,559
SC 13G/A
Feb 09, 2023
vanguard group inc
6.25%
1,776,908
SC 13G/A

Recent SEC filings of AnaptysBio Inc

View All Filings
Date Filed Form Type Document
Feb 21, 2024
4
Insider Trading
Feb 16, 2024
144
Notice of Insider Sale Intent
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 01, 2024
4
Insider Trading
Jan 30, 2024
144
Notice of Insider Sale Intent
Jan 26, 2024
SC 13G/A
Major Ownership Report
Jan 09, 2024
4
Insider Trading

Peers (Alternatives to AnaptysBio Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.4B
9.1B
-16.59% -47.80%
-9.64
3.66
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
19.5B
1.8B
-23.99% -31.71%
-44.27
10.66
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.44
7.22
15.05% 75.21%
13.5B
3.7B
-7.62% -26.87%
22.67
3.67
8.87% 75.42%
MID-CAP
7.9B
272.9M
-2.06% 34.31%
-13.08
29.05
141.38% 4.43%
5.9B
107.9M
-3.85% 226.12%
-9.53
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.44
6.46
23.54% 31.53%
3.9B
223.4M
8.92% 47.81%
-19.25
17.39
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.18
15.02
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.56
4.2
81.69% -7.29%
472.8M
1.0B
-9.17% -57.89%
-0.86
0.45
-43.15% 58.48%
179.5M
4.9M
-14.18% -58.18%
-1.09
36.72
-57.57% 50.48%
120.1M
881.7K
289.54% 381.25%
-2.53
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

AnaptysBio Inc News

Latest updates
MSN5 hours ago
Seeking Alpha16 Feb 202405:21 pm
InvestorsObserver16 Feb 202403:42 pm
InvestorsObserver05 Feb 202408:00 am

AnaptysBio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue4.3%4,854,0004,653,0004,486,0006,576,0002,262,0001,107,0001,059,0001,011,00020,890,00030,027,00011,247,00060,000,000--15,000,0003,000,000-5,000,0002,500,000-5,000,000
Operating Expenses-5.9%41,050,00043,603,00045,775,00032,781,00030,926,00029,015,00032,719,00032,168,00027,653,00030,560,00029,608,00026,655,00024,336,00022,635,00025,253,00025,258,00033,745,00031,657,00024,772,00019,663,00021,887,000
  S&GA Expenses-4.8%10,172,00010,680,00010,818,0009,407,0008,862,0008,171,00010,203,0005,392,0005,432,0005,246,0005,423,0005,088,0004,794,0004,687,0004,285,0003,832,0003,814,0004,307,0004,141,0003,743,0004,004,000
  R&D Expenses-6.2%30,878,00032,923,00034,957,00023,374,00022,064,00020,844,00022,516,00026,776,00022,221,00025,314,00024,185,00021,567,00019,542,00017,948,00020,968,00021,426,00029,931,00027,350,00020,631,00015,920,00017,883,000
EBITDA Margin12.6%-6.22-7.12-8.87-12.45-2.43-1.56-1.14-0.91-0.16-0.19-0.27-0.26---------
Interest Expenses---------------4,000200,000240,000281,000320,000365,000400,000
Income Taxes-----------------22,000-51,000-60,000-19,000-192,000-
Earnings Before Taxes------------33,646,000-23,767,000-21,548,000-8,262,000-20,285,000-31,084,000-24,022,000-22,097,000-17,186,000-15,958,000
EBT Margin12.6%-6.26-7.16-8.92-12.51-2.46-1.57-1.16-0.91-0.16-0.20-0.28-0.27---------
Net Income6.4%-37,308,000-39,845,000-44,255,000-26,413,000-33,502,000-32,554,000-36,255,000-32,538,000-6,666,000-429,000-18,163,00033,646,000-23,767,000-21,548,000-8,262,000-20,263,000-31,033,000-23,962,000-22,078,000-16,994,000-15,958,000
Net Income Margin10.3%-7.19-8.01-9.47-12.51-5.74-2.94-1.52-0.910.07-0.09-0.42-0.27---------
Free Cashflow-43.1%-36,636,000-25,599,000-24,743,000-10,860,000-17,797,000-24,225,000-21,069,000-25,315,000-7,178,0008,728,000-23,521,00037,267,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-5.8%487517552610619604625643424427396417385402424435452480494509523
  Current Assets-2.4%428439437447450453512554387398387397346385371378425431422434503
    Cash Equivalents-25.3%26.0035.0095.0071.0059.0072.00166496336332284251209221165171183147106114293
  Net PPE11.4%2.002.002.002.002.002.002.002.002.002.002.002.002.001.002.002.002.001.002.001.001.00
  Current Liabilities-5.9%39.0042.0036.0026.0021.0020.0020.0016.0021.0021.0014.0020.0024.0020.0023.0030.0030.0031.0025.0022.0021.00
Shareholder's Equity-18.9%120148191262278304331356384386382397360381401405421448468486500
  Retained Earnings-7.0%-571-534-494-450-424-390-358-321-289-282-282-263-297-273-252-244-223-192-168-146-129
  Additional Paid-In Capital1.2%695687689718708699691679673668664661658654652649644641637633630
Shares Outstanding0.2%27.0027.0027.0029.0028.0028.0028.0028.0027.0027.0027.0027.00---------
Float------400---489---556---1,391---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-43.5%-36,474-25,409-24,568-10,685-17,747-24,147-21,014-25,301-7,0069,591-23,20437,578-17,013-19,610-15,112-15,805-22,096-15,517-16,099-12,290-14,860
  Share Based Compensation3.4%3,0002,9008,860-3,0002,9007,742-4,3643,6903,315----------
Cashflow From Investing249.8%30,635-20,45585,39621,497-32,434-70,996-312,912-66,69410,83937,96156,7293,5984,73275,39410,7514,03559,86357,8769,657-166,15024,615
Cashflow From Financing77.2%-3,072-13,492-37,5741,94937,0274324,609251,33624155416712626371.00-1,339-111-1,421-1,660-1,301-1,372226,596
  Buy Backs-100.1%-13.0011,65638,816------------------

ANAB Income Statement

2023-09-30
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Collaboration revenue$ 3,318$ 1,293$ 8,152$ 3,479
Operating expenses:    
Research and development30,87822,06498,75865,424
General and administrative10,1728,86231,67027,236
Total operating expenses41,05030,926130,42892,660
Loss from operations(37,732)(29,633)(122,276)(89,181)
Other income (expense), net:    
Interest income4,8542,26213,9933,711
Non-cash interest expense for the sale of future royalties(4,431)(6,135)(13,125)(16,857)
Other income, net14016
Total other income (expense), net424(3,869)868(13,130)
Net loss(37,308)(33,502)(121,408)(102,311)
Unrealized gain (loss) on available for sale securities1,261(2,146)2,896(5,585)
Comprehensive loss$ (36,047)$ (35,648)$ (118,512)$ (107,896)
Net loss per common share:    
Basic (in dollars per share)$ (1.41)$ (1.18)$ (4.49)$ (3.64)
Diluted (in dollars per share)$ (1.41)$ (1.18)$ (4.49)$ (3.64)
Weighted-average number of shares outstanding:    
Basic (in shares)26,54628,28927,03828,071
Diluted (in shares)26,54628,28927,03828,071
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Collaboration Revenue [Member]Collaboration Revenue [Member]Collaboration Revenue [Member]Collaboration Revenue [Member]

ANAB Balance Sheet

2023-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 26,295$ 71,308
Receivables from collaborative partners3,2691,419
Short-term investments386,752369,933
Prepaid expenses and other current assets11,6844,545
Total current assets428,000447,205
Property and equipment, net2,2542,089
Operating lease right-of-use assets16,61317,898
Long-term investments40,203142,935
Other long-term assets256256
Total assets487,326610,383
Current liabilities:  
Accounts payable6,5212,784
Accrued expenses30,91621,633
Current portion of operating lease liability1,7411,637
Total current liabilities39,17826,054
Liability related to sale of future royalties311,272304,413
Operating lease liability, net of current portion16,49317,813
Stockholders’ equity:  
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2023 and December 31, 2022, respectively00
Common stock, $0.001 par value, 500,000 shares authorized, 26,575 shares and 28,513 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively2729
Additional paid in capital694,591717,797
Accumulated other comprehensive loss(2,350)(5,246)
Accumulated deficit(571,885)(450,477)
Total stockholders’ equity120,383262,103
Total liabilities and stockholders’ equity$ 487,326$ 610,383
ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
 CEO
 WEBSITEwww.anaptysbio.com
 EMPLOYEES96

AnaptysBio Inc Frequently Asked Questions


What is the ticker symbol for AnaptysBio Inc? What does ANAB stand for in stocks?

ANAB is the stock ticker symbol of AnaptysBio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AnaptysBio Inc (ANAB)?

As of Wed Feb 21 2024, market cap of AnaptysBio Inc is 677.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANAB stock?

You can check ANAB's fair value in chart for subscribers.

What is the fair value of ANAB stock?

You can check ANAB's fair value in chart for subscribers. The fair value of AnaptysBio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AnaptysBio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AnaptysBio Inc a good stock to buy?

The fair value guage provides a quick view whether ANAB is over valued or under valued. Whether AnaptysBio Inc is cheap or expensive depends on the assumptions which impact AnaptysBio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANAB.

What is AnaptysBio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 21 2024, ANAB's PE ratio (Price to Earnings) is -4.58 and Price to Sales (PS) ratio is 32.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANAB PE ratio will change depending on the future growth rate expectations of investors.